Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Individualized therapy for metastatic colorectal cancer.

Silvestri A, Pin E, Huijbers A, Pellicani R, Parasido EM, Pierobon M, Petricoin E, Liotta L, Belluco C.

J Intern Med. 2013 Jul;274(1):1-24. doi: 10.1111/joim.12070. Epub 2013 Apr 12. Review.

2.

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F.

J Clin Oncol. 2009 Dec 10;27(35):5924-30. doi: 10.1200/JCO.2008.21.6796. Epub 2009 Nov 2.

PMID:
19884556
3.

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.

Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25. Review.

PMID:
24666267
4.

Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies.

Hawkes E, Cunningham D.

J Clin Oncol. 2010 Oct 1;28(28):e529-31; author reply e532-e533. doi: 10.1200/JCO.2010.29.5626. Epub 2010 Aug 2. No abstract available.

PMID:
20679615
5.

The forest and the trees: pathways and proteins as colorectal cancer biomarkers.

Bertagnolli MM.

J Clin Oncol. 2009 Dec 10;27(35):5866-7. doi: 10.1200/JCO.2009.24.8013. Epub 2009 Nov 2. No abstract available.

PMID:
19884524
6.

Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.

Kleist B, Kempa M, Novy M, Oberkanins C, Xu L, Li G, Loland C, Poetsch M.

Int J Clin Exp Pathol. 2014 Aug 15;7(9):5927-39. eCollection 2014.

7.

Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?

Hawkes E, Cunningham D.

Lancet Oncol. 2010 Nov;11(11):1020-1. doi: 10.1016/S1470-2045(10)70211-4. No abstract available.

PMID:
21051017
8.

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.

PMID:
23429431
9.

Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.

Park JH, Han SW, Oh DY, Im SA, Jeong SY, Park KJ, Kim TY, Bang YJ, Park JG.

Cancer Chemother Pharmacol. 2011 Oct;68(4):1045-55. doi: 10.1007/s00280-011-1586-z. Epub 2011 Feb 22.

PMID:
21340604
10.

Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.

Takahashi N, Yamada Y, Taniguchi H, Honma Y, Iwasa S, Kato K, Hamaguchi T, Shimada Y.

Arch Med Res. 2014 Jul;45(5):366-74. doi: 10.1016/j.arcmed.2014.05.004. Epub 2014 May 13. Erratum in: Arch Med Res. 2014 Aug;45(6):515.

PMID:
24830936
11.

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.

Tian S, Simon I, Moreno V, Roepman P, Tabernero J, Snel M, van't Veer L, Salazar R, Bernards R, Capella G.

Gut. 2013 Apr;62(4):540-9. doi: 10.1136/gutjnl-2012-302423. Epub 2012 Jul 14.

12.

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.

Dienstmann R, Serpico D, Rodon J, Saura C, Macarulla T, Elez E, Alsina M, Capdevila J, Perez-Garcia J, Sánchez-Ollé G, Aura C, Prudkin L, Landolfi S, Hernández-Losa J, Vivancos A, Tabernero J.

Mol Cancer Ther. 2012 Sep;11(9):2062-71. doi: 10.1158/1535-7163.MCT-12-0290. Epub 2012 Jun 21.

13.

Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies.

Wong R, Cunningham D.

J Clin Oncol. 2008 Dec 10;26(35):5668-70. doi: 10.1200/JCO.2008.19.5024. Epub 2008 Nov 10. No abstract available. Erratum in: J Clin Oncol. 2009 Jun 20;27(18):3070.

PMID:
19001346
14.

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.

László L.

Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.

15.

What can molecular pathology offer for optimal decision making?

Aust DE, Sommer U, Baretton GB.

Ann Oncol. 2012 Sep;23 Suppl 10:x63-70.

PMID:
22987994
16.

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F, Russo A.

Cancer Treat Rev. 2010 Nov;36 Suppl 3:S56-61. doi: 10.1016/S0305-7372(10)70021-9. Review.

PMID:
21129611
17.

[Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].

Fabian P, Berkovcová J.

Cesk Patol. 2011 Oct;47(4):154-8. Review. Czech.

PMID:
22145213
18.

Predictive and prognostic markers in colorectal cancer.

George B, Kopetz S.

Curr Oncol Rep. 2011 Jun;13(3):206-15. doi: 10.1007/s11912-011-0162-3. Review.

PMID:
21373987
19.

Predictive factors to targeted treatment in gastrointestinal carcinomas.

Silvestris N, Marech I, Brunetti AE, Azzariti A, Numico G, Cicero G, Delcuratolo S, De Luca R, Burz C, Lorusso V.

Cancer Biomark. 2014;14(2-3):151-62. doi: 10.3233/CBM-130327. Review.

PMID:
24878816
20.

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?

Inno A, Di Salvatore M, Cenci T, Martini M, Orlandi A, Strippoli A, Ferrara AM, Bagalà C, Cassano A, Larocca LM, Barone C.

Clin Colorectal Cancer. 2011 Dec;10(4):325-32. doi: 10.1016/j.clcc.2011.03.028. Epub 2011 May 11.

PMID:
21729677

Supplemental Content

Support Center